Jubilant Pharmova Limited has announced the completion of a USFDA inspection at its contract manufacturing facility, Jubilant HollisterStier LLC (JHS), located in Spokane, WA, USA. The inspection, which concluded on June 17, 2026, resulted in eight observations, none of which were related to sterility assurance concerns. JHS is committed to addressing all observations comprehensively within 15 business days.
USFDA Inspection Concludes at Spokane Facility
Jubilant Pharmova Limited has confirmed the conclusion of an inspection by the United States Food and Drug Administration (USFDA) at its contract manufacturing facility, Jubilant HollisterStier LLC (JHS), in Spokane, Washington, U.S.A. The inspection took place on June 17, 2026.
Inspection Outcome and Response
During the inspection, the USFDA issued a total of eight (8) observations. Importantly, none of these observations pertained to sterility assurance concerns, a critical aspect for sterile injectables. Jubilant HollisterStier LLC will provide a detailed response to these observations within 15 business days. The company has expressed its commitment to comprehensively addressing all points raised during the inspection.
About Jubilant HollisterStier LLC
Jubilant HollisterStier LLC is a leading integrated contract manufacturer specializing in sterile injectables (including liquid and lyophilization) and ophthalmics. With facilities in North America, JHS offers specialized manufacturing services to the pharmaceutical and biopharmaceutical industries, providing end-to-end support from process qualifications to commercial release.
About Jubilant Pharmova Limited
Jubilant Pharmova Limited is an integrated global pharmaceutical company engaged in businesses such as Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing of sterile injectables, and Generics. The company operates multiple manufacturing facilities catering to regulated markets worldwide and is recognized as a ‘Partner of Choice’ by leading pharmaceutical companies.
Source: BSE
